Chikungunya Fever

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Chikungunya virus is an alphavirus that is arthropod-borne and transmitted by Aedes mosquitoes. This virus causes a rash, an acute febrile illness, and arthralgia known as chikungunya fever which can develop into potentially chronic and debilitating arthritis that may last for months or years. This activity illustrates the evaluation and treatment of chikungunya fever and reviews the role of the interprofessional team in improving care for patients with this condition.

Objectives:

  • Identify the mosquito vectors in the etiology of chikungunya fever.
  • Outline the epidemiology of chikungunya fever.
  • Describe the patient history associated with chikungunya fever.
  • Review the importance of collaboration and communication among the interprofessional team to enhance preventive measures and improve outcomes for chikungunya fever.

Introduction

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus that belongs to the family Togaviridae transmitted by Aedes mosquitoes. The virus is known for causing an acute febrile illness, rash, and arthralgia known as Chikungunya fever followed by potentially chronic and debilitating arthritic symptoms that may last for months or years.[1] Historically, CHIKV was found mainly in Africa and Asia, initially isolated in the Makonde Plateau in Tanzania in 1952.[2] The name Chikungunya is derived from a Makonde phrase meaning, "that which bends up." The worst outbreak reported occurred in the Reunion Island in 2005-2006 affecting nearly 35% of the population.[3] Since 2005, cases of Chikungunya fever have spread mainly in tropical and sub-tropical regions finally reaching the Americas via the Caribbean island of St. Martin in 2013.[4] Today, CHIKV is widespread worldwide and is a global public health concern.

Etiology

The primary vectors for CHIKV are Aedes aegypti and Ae. albopictus (Asian Tiger mosquito). These mosquitoes have biological characteristics that provide effective invasiveness, vector competence, and vectorial capacity that sets the tone for the global manifestation of Chikungunya fever.[5] Invasiveness is highlighted by the species' preference for human blood and its historically-proven ability to establish outside of their native range. Vector competence is determined by the species' physiological characteristics that allow for transmission, such as virus ingestion with blood meal and subsequent infection of the mosquitoes’ salivary glands.[6] Most importantly, vector capacity determines outbreak potential and is mainly influenced by intrinsic (mosquito infection barriers and genetics) and extrinsic (environmental issues) factors. Vector density in relation to the host, the probability that vector feeds on a host in one day, vector survivability, and extrinsic incubation period are all vector competence factors that determine infectivity directly.[7]

Ae. aegypti has been established in the U.S. for more than 300 years while Ae. albopictus has been present since 1985 with different vector characteristics making global expansion of the disease possible. Specifically, CHIKV was found to have adapted to Ae. albopictus fairly recently during the Indian Ocean outbreak in 2005-06 when it acquired a mutation in its E1 membrane protein that allowed it to infest the urban mosquito vector.[8] In general, the threat to public health posed by Ae. aegypti and Ae. albopictus mosquitoes is a function of their focused feeding on and association with humans along with the ability of the human host and mosquito vector to travel.[9]

Epidemiology

CHIKV was first discovered in Tanzania in 1952, has since spread effectively reaching the Americas in 2013, Florida on July 2014, and severely affecting various Caribbean, Central, and South American countries after that.[10] Although the CHIKV virus is considered to be endemic in certain parts of West Africa, global distribution has been facilitated by both human and vector travel. Infected travelers import CHIKV into new areas where local Aedes mosquitoes initiate local transmission.[11] Mosquito larvae and egg transport by ships and air traffic has also been described as dissemination means for mosquitoes into naive and suitable environments.[12] Transmission is mostly via mosquito bites, although maternal-fetal and blood product transmission was also described during the Reunion Island outbreaks.[13]

Ae. aegypti and Ae. albopictus are also the vectors responsible for other notable diseases such as Dengue and Zika, causing coinfection in some cases.[14] Given the similarity in clinical presentation and nearly identical geographic distribution, and differentiation of disease has become an issue.

Pathophysiology

CHIKV is known to transmit in 2 cycles: urban and sylvatic. Urban transmission is from human to mosquito to human and is the main source of the current Western Hemisphere epidemic. Sylvatic transmission can be found in Africa and is based on animal to mosquito to human.[15] As mentioned previously, CHIKV was initially transmitted through the vector Ae. aegypti, but incorporation of Ae. albopictus through a mutation in the E1 envelope protein not only increased the fitness of the virus in this species but improved transmissibility to vertebrates.[16][17]

The route of infection used by CHIKV starts after inoculation and infection of human epithelial and endothelial cells, primary fibroblasts, and monocyte-derived macrophages.[18] After an initial immune response and sheltering in the lymph nodes, CHIKV travels through the lymphatic and circulatory system causing significant viremia.[19] Transportation into target organs (muscles, joints, liver, and brain) has been found to be caused by infected monocyte-derived macrophages.[18] Inflammatory reaction mediated by CD8+ (acute), CD4+ T lymphocytes, and pro-inflammatory cytokines are thought to be responsible for the acute symptoms, while a persistent reservoir of infected monocytes in the joints may be responsible for chronic joint disease.[20]

Histopathology

CHIKV is an arthropod-carried pathogen of the genus alphavirus and the family Togaviridae that possesses 3 known genotypes: Asian, West African, and East Central South African.[21] The virus is described as a positive-sense, single-stranded RNA virus, and sensitive to temperatures greater than 58 C.[17]

History and Physical

Chikungunya fever usually presents with the non-specific findings of high-grade fever and myalgia, following a 3 to 7 day incubation period, and lasting around 3 to 5 days. Bilateral symmetrical polyarthralgia ensues 2 to 5 days after the onset of fevers and preferentially involves distal over proximal joints.[22] The hands have been found to be affected the most with some involvement reported to the axial skeleton, knees, and ankles accompanied by intense pain that lasts between one and three weeks.[23] Another common clinical manifestation is a generalized maculopapular rash that usually involves the extremities first and arises 3 days after the fever symptoms.[24] Although rare, vesiculobullous and mucocutaneous lesions have also been reported.[25][26]

Manifestations such as abdominal pain, diarrhea, vomiting, and generalized lymphadenopathy may also be found. Although it is not considered to be a neurotropic virus, it has long been associated with neurologic symptoms, with encephalitis among newborns infected through mother-to-child transmission being the most common.[27] In a 2018 study in Puerto Rico, red eyes, conjunctivitis, and anterior uveitis were frequently found in patients with Chikungunya fever.[28] Other studies have described recurrent retinitis,[29] congenital ocular symptoms,[30] sepsis/septic shock,[31] and renal manifestations.[32]

Evaluation

Chikungunya fever evaluation consists mainly of the clinical findings of fever and polyarthralgia in a person who recently returned from an affected region with an 84% sensitivity, 71% positive predictive value (PPV), and 83% negative predictive value (NPV).[33] However, overlap of endemic and invaded CHIKV and Dengue virus (DENV) areas makes evaluation and differentiation of disease difficult. CHIKV is more likely to cause high fever, severe arthralgia, arthritis, rash, and lymphopenia, while DENV is more likely to cause neutropenia, thrombocytopenia, hemorrhage shock, and death.[34] In light of this, WHO recommends treating everyone for DENV until proven otherwise to improve outcomes. 

Diagnosis of CHIKV can be established or confirmed by detection of viral RNA with serology and/or reverse-transcription polymerase chain reaction (RT-PCR) depending on disease timeframe presentation.[35] RT-PCR is mainly used during acute infection, during the first five days of disease for best results. On the other hand, viral serology using enzyme-linked immunosorbent assay (ELISA) or indirect fluorescent antibody (IFA) is used for detection of anti-chikungunya antibodies IgM (present from five days to several weeks) and IgG (present from two weeks to several years), depending on the stage of disease.[36][37] The CDC and WHO recommend gathering serology for CHIKV, DENV, and Zika virus (ZV) for all patients with suspicious clinical symptoms.[38]

Chikungunya fever is a nationally notifiable condition.

Treatment / Management

Symptomatic relief is the mainstay treatment for Chikungunya fever, including adequate hydration, rest, and pain/fever relief preferably with acetaminophen.[39] WHO discourages the use of aspirin and most nonsteroidal anti-inflammatory drugs (NSAIDs) during the first 48 hours due to the risk of aggravating platelet dysfunction, especially in cases of possible DENV coinfection. Other studies advocate for the efficacy of low-dose corticosteroid drugs for the first 2 months of post-acute disease.[40] Ocular manifestations including anterior and posterior uveitis have been treated with topical steroids and cycloplegics.[41]

Chronic manifestations, including persistent or relapsing-remitting polyarthralgia, polyarthritis, and myalgia, have been found to respond adequately to hydroxychloroquine in combination with corticosteroids or other disease modifying anti-rheumatic drugs (DMARDs).[42][43] Specific antivirals targeting viral replication using siRNAs[44] and virus entry/replication[45] are showing promising results but have not been approved for human use.[46]

Management of CHIKV is based on avoidance of mosquito bites. Use of repellents containing DEET, wearing protective clothing, bed nets, and air-conditioned buildings are great ways to prevent exposure.[47] Furthermore, prevention of mosquito proliferation should be implemented by reduction of peri-domiciliary water puddles.[23] Insecticides have been another means of vector management using four types of drugs: carbamates, organochlorides, organophosphates, and pyrethroids. Nonetheless, insecticide resistance of Ae. aegypti and Ae. albopictus has been of increasing concern.[48] Vaccines are also a hot topic for research and development, but none have yet been approved for patient use.[49]

Differential Diagnosis

Given the non-specific findings of arthralgia, high fever, and rash, the differential diagnosis for the acute and chronic manifestations of Chikungunya fever can be extensive. As mentioned above, DENV and ZK share not only clinical findings but also identical vectors with CHIKV, which prompts serology testing for all 3 viruses when a patient presents with the above symptoms.[38] Other infections that should be considered include:

  • Malaria
  • Yellow fever
  • Leptospirosis
  • Measles
  • Mononucleosis
  • African tick bite fever

Chronic arthralgia caused by Chikungunya fever can be easily confused with other more common causes. Furthermore, worse outcomes and increased morbidity has been demonstrated for patients with underlying joint disease and are super-infected with CHIKV.[50] The differential diagnosis for chronic manifestations includes:

  • Seronegative rheumatoid arthritis
  • Reiter arthritis
  • Rheumatoid arthritis 
  • Hepatitis C
  • Systemic lLupus erythematosus

Prognosis

Despite a low case fatality ratio (CFR), Chikungunya fever is highlighted by a substantial post-chikungunya chronic polyarthralgia, defined as joint pains lasting longer than 6 weeks.[51] A study published in 2018, composed of Aruba CHIKV cases, reported that 26% of all serology-confirmed infected patients presented with post-chikungunya polyarthritis.[52] Another study published in 2018, from 2014 French Guiana, reported post-CHIKV rheumatic or musculoskeletal pain at 3 and 6 months of 40% and 31.3% respectively of all RT-PCR proven cases.[50]

Complications

As mentioned previously, chronic arthritis is the most common and serious complication of Chikungunya fever. Ocular manifestations of disease can include conjunctivitis, optic neuritis, iridocyclitis, episcleritis, retinitis, and uveitis.[53] The most common complications are iridocyclitis and retinitis and have been found to be typically benign and self-limited.[54]

Consultations

Chronic arthritis from Chikungunya fever has emerged as a concern for rheumatologist specialists worldwide due to swelling and recurrent pain that poorly responds to treatment with analgesics, and because it is a debilitating disease that mimics rheumatic arthritis and compromises the quality of life.[55][56]

Deterrence and Patient Education

Chikungunya fever is a virus transmitted to people by mosquitoes found mainly in tropical and sub-tropical environments. Originating from Asia, this disease has caused serious outbreaks in the Western Hemisphere since 2013. The most common symptoms of this disease are high fevers and joint pain, although headaches, muscle pains, and rash may also occur. Risk factors for the disease consist of travel to affected areas or anywhere with mosquitoes and mosquito bites. Treatment consists of rest, adequate hydration, and pain relief with acetaminophen. Prevention is key and is based on protection from mosquito bites with clothing, DEET, and mosquito nets. Given the risk of co-infection with other viruses from the mosquito bite, individuals with these symptoms must seek medical care immediately.

Pearls and Other Issues

  • Chikungunya fever is an arthropod-borne alphavirus from the Togaviridae family endemic to Asia that is transmitted by Aedes aegypti and Aedes albopictus mosquitoes and has caused serious worldwide outbreaks with a preference for tropical and sub-tropical climates.
  • The Aedes mosquito vectors are also responsible for transmitting Dengue virus and Zika virus, so co-infection is possible.
  • Acute clinical manifestations of high fevers, polyarthralgia, and maculopapular rash begin after a 3- to 7-day incubation accompanied by a headache and myalgia. Ocular, neurological, and fetal manifestations have been found in rare instances.
  • Chronic arthritis is the most common and severe complication leading to specialist rheumatologic care.
  • Diagnosis is obtained with the above clinical findings accompanied by a history of recent travel to an affected area or exposure to mosquito bites. Diagnosis confirmation is performed with RT-PCR or viral serology. The CDC recommends that all patients with exposure and symptoms be tested for CHIKV, DENV, and ZK.
  • Supportive care with rest, hydration, and analgesic agents is the mainstay treatment. Aspirin and NSAIDs should be avoided initially for risk of co-infection with DENV. Chronic manifestations can be treated with steroids and disease-modifying anti-rheumatic drugs (DMARDs). No antivirals or vaccines are commonly used.
  • Prevention with avoidance of mosquito bites is paramount. DEET, clothing with coverage, and mosquito nets. Insecticides have been used as a public health measure, but resistance is a factor of increased concern.
  • Chikungunya fever is a reportable disease to the CDC.

Enhancing Healthcare Team Outcomes

Mosquitoes represent the arthropod-vector with the most impact in the world, transmitting diseases from Chikungunya fever to malaria with incalculable morbidity and mortality. Given the lack of specific treatment for most of these diseases, vector control remains the main form of prevention. Insecticide public health campaigns have proven to be effective in the past, but widespread resistance has put a dent on these efforts.[57] (Level V) Another focus of prevention proven in Brazilian studies has been personal protection and individual actions including use of DEET, bed nets, light-colored long-sleeve clothing, and reduction of peri-domiciliary water puddles/reservoirs.[58] (Level I)

When it comes to improving outcomes, the CDC has highlighted the dangers of CHIKV and DENV co-infection and the differences in treatment modalities, important for all healthcare professionals, to avoid Dengue fever-related deaths.[59] A 2018 review highlighted the importance of proper diagnosis (gathering serology DENV, CHIKV, and ZV serology on affected individuals), surveillance, and management to avoid poor prognosis.[60] (Level I)

Details

Author

Jafet A. Ojeda Rodriguez

Author

Anthony Haftel

Editor:

J R. Walker, III

Updated:

6/26/2023 9:23:49 PM

Feedback:

Send Us Your Comments

References

[1]

Horwood PF, Buchy P. Chikungunya. Revue scientifique et technique (International Office of Epizootics). 2015 Aug:34(2):479-89     [PubMed PMID: 26601450]

[2]

ROBINSON MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1955 Jan:49(1):28-32     [PubMed PMID: 14373834]

[3]

Renault P, Balleydier E, D'Ortenzio E, Bâville M, Filleul L. Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Medecine et maladies infectieuses. 2012 Mar:42(3):93-101. doi: 10.1016/j.medmal.2011.12.002. Epub 2012 Jan 26     [PubMed PMID: 22280563]

[4]

Rougeron V,Sam IC,Caron M,Nkoghe D,Leroy E,Roques P, Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Mar     [PubMed PMID: 25453326]

[5]

Fernández-Salas I, Danis-Lozano R, Casas-Martínez M, Ulloa A, Bond JG, Marina CF, Lopez-Ordóñez T, Elizondo-Quiroga A, Torres-Monzón JA, Díaz-González EE. Historical inability to control Aedes aegypti as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral research. 2015 Dec:124():30-42. doi: 10.1016/j.antiviral.2015.10.015. Epub 2015 Oct 27     [PubMed PMID: 26518229]

[6]

Higgs S, Vanlandingham D. Chikungunya virus and its mosquito vectors. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2015 Apr:15(4):231-40. doi: 10.1089/vbz.2014.1745. Epub 2015 Feb 12     [PubMed PMID: 25674945]

[7]

Kramer LD,Ciota AT, Dissecting vectorial capacity for mosquito-borne viruses. Current opinion in virology. 2015 Dec     [PubMed PMID: 26569343]

Level 3 (low-level) evidence

[8]

Cunze S,Kochmann J,Koch LK,Klimpel S, Niche conservatism of Aedes albopictus and Aedes aegypti - two mosquito species with different invasion histories. Scientific reports. 2018 May 16     [PubMed PMID: 29769652]

[9]

Lounibos LP, Kramer LD. Invasiveness of Aedes aegypti and Aedes albopictus and Vectorial Capacity for Chikungunya Virus. The Journal of infectious diseases. 2016 Dec 15:214(suppl 5):S453-S458     [PubMed PMID: 27920173]

[10]

Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral research. 2015 Aug:120():32-9. doi: 10.1016/j.antiviral.2015.04.016. Epub 2015 May 12     [PubMed PMID: 25979669]

[11]

Pialoux G,Gaüzère BA,Jauréguiberry S,Strobel M, Chikungunya, an epidemic arbovirosis. The Lancet. Infectious diseases. 2007 May     [PubMed PMID: 17448935]

[12]

Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. Aedes albopictus, an arbovirus vector: from the darkness to the light. Microbes and infection. 2009 Dec:11(14-15):1177-85. doi: 10.1016/j.micinf.2009.05.005. Epub 2009 May 18     [PubMed PMID: 19450706]

[13]

Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis. PLoS neglected tropical diseases. 2018 Jun:12(6):e0006510. doi: 10.1371/journal.pntd.0006510. Epub 2018 Jun 13     [PubMed PMID: 29897898]

Level 1 (high-level) evidence

[14]

Clinical profile of dengue fever and coinfection with chikungunya., Singh J,Dinkar A,Singh RG,Siddiqui MS,Sinha N,Singh SK,, Ci ji yi xue za zhi = Tzu-chi medical journal, 2018 Jul-Sep     [PubMed PMID: 30069124]

[15]

Singh SK, Unni SK. Chikungunya virus: host pathogen interaction. Reviews in medical virology. 2011 Mar:21(2):78-88. doi: 10.1002/rmv.681. Epub 2011 Mar 15     [PubMed PMID: 21412934]

[16]

Lum FM, Ng LF. Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral research. 2015 Aug:120():165-74. doi: 10.1016/j.antiviral.2015.06.009. Epub 2015 Jun 16     [PubMed PMID: 26092642]

[17]

Ganesan VK,Duan B,Reid SP, Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017 Dec 1     [PubMed PMID: 29194359]

[18]

Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. Characterization of reemerging chikungunya virus. PLoS pathogens. 2007 Jun:3(6):e89     [PubMed PMID: 17604450]

[19]

Kam YW, Ong EK, Rénia L, Tong JC, Ng LF. Immuno-biology of Chikungunya and implications for disease intervention. Microbes and infection. 2009 Dec:11(14-15):1186-96. doi: 10.1016/j.micinf.2009.09.003. Epub 2009 Sep 6     [PubMed PMID: 19737625]

[20]

Chow A,Her Z,Ong EK,Chen JM,Dimatatac F,Kwek DJ,Barkham T,Yang H,Rénia L,Leo YS,Ng LF, Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. The Journal of infectious diseases. 2011 Jan 15     [PubMed PMID: 21288813]

[21]

Caglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. Chikungunya virus infection: an overview. The new microbiologica. 2013 Jul:36(3):211-27     [PubMed PMID: 23912863]

Level 3 (low-level) evidence

[22]

Hua C, Combe B. Chikungunya Virus-Associated Disease. Current rheumatology reports. 2017 Oct 5:19(11):69. doi: 10.1007/s11926-017-0694-0. Epub 2017 Oct 5     [PubMed PMID: 28983760]

[23]

Madariaga M,Ticona E,Resurrecion C, Chikungunya: bending over the Americas and the rest of the world. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016 Jan-Feb     [PubMed PMID: 26707971]

[24]

Tini ML, Rezza G. Morbilliform skin rash with prominent involvement of the palms in Chikungunya fever. IDCases. 2018:13():e00421. doi: 10.1016/j.idcr.2018.e00421. Epub 2018 Jul 4     [PubMed PMID: 30101066]

Level 3 (low-level) evidence

[25]

Pakran J,George M,Riyaz N,Arakkal R,George S,Rajan U,Khader A,Thomas S,Abdurahman R,Sasidharanpillai S,Thumbayil L, Purpuric macules with vesiculobullous lesions: a novel manifestation of Chikungunya. International journal of dermatology. 2011 Jan     [PubMed PMID: 21182504]

[26]

Bandyopadhyay D,Ghosh SK, Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. International journal of dermatology. 2008 Nov     [PubMed PMID: 18986446]

[27]

Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. Reviews in medical virology. 2009 May:19(3):121-9. doi: 10.1002/rmv.606. Epub     [PubMed PMID: 19274635]

[28]

Ulloa-Padilla JP,Dávila PJ,Izquierdo NJ,García-Rodríguez O,Jiménez IZ, Ocular Symptoms and Signs of Chikungunya Fever in Puerto Rico. Puerto Rico health sciences journal. 2018 Jun     [PubMed PMID: 29905918]

[29]

Salceanu SO,Raman V, Recurrent chikungunya retinitis. BMJ case reports. 2018 Aug 27     [PubMed PMID: 30150331]

Level 3 (low-level) evidence

[30]

Merle H, Donnio A, Jean-Charles A, Guyomarch J, Hage R, Najioullah F, Césaire R, Cabié A. [Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever (French translation of the article)]. Journal francais d'ophtalmologie. 2018 Sep:41(7):659-668. doi: 10.1016/j.jfo.2018.03.005. Epub 2018 Aug 31     [PubMed PMID: 30173871]

[31]

Severe Manifestations of Chikungunya Fever in Children, India, 2016., Sharma PK,Kumar M,Aggarwal GK,Kumar V,Srivastava RD,Sahani A,Goyal R,, Emerging infectious diseases, 2018 Sep     [PubMed PMID: 30124414]

[32]

Rajapakse S,Rodrigo C,Rajapakse A, Atypical manifestations of chikungunya infection. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010 Feb     [PubMed PMID: 19716149]

[33]

Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral research. 2013 Sep:99(3):345-70. doi: 10.1016/j.antiviral.2013.06.009. Epub 2013 Jun 28     [PubMed PMID: 23811281]

[34]

Le Coupanec A, Tchankouo-Nguetcheu S, Roux P, Khun H, Huerre M, Morales-Vargas R, Enguehard M, Lavillette D, Missé D, Choumet V. Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes. International journal of molecular sciences. 2017 Aug 4:18(8):. doi: 10.3390/ijms18081708. Epub 2017 Aug 4     [PubMed PMID: 28777313]

[35]

Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri JS, Bhatnagar RK, Kaja MK, Chandele A, Sunil S. Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jul 1:65(1):133-140. doi: 10.1093/cid/cix283. Epub     [PubMed PMID: 28379375]

[36]

Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerging infectious diseases. 2008 Mar:14(3):416-22. doi: 10.3201/eid1403.070906. Epub     [PubMed PMID: 18325256]

[37]

Kumar P, Pok KY, Tan LK, Angela C, Leo YS, Ng LC. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection. Journal of virological methods. 2014 Sep:206():67-75. doi: 10.1016/j.jviromet.2014.05.014. Epub 2014 May 29     [PubMed PMID: 24880071]

[38]

Loconsole D, Metallo A, De Robertis AL, Morea A, Quarto M, Chironna M. Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2018 Jun:18(6):331-334. doi: 10.1089/vbz.2017.2260. Epub 2018 Apr 23     [PubMed PMID: 29683399]

[39]

Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P, Franco JM, Caumes E, Combe B, Poiraudeau S, Gane-Troplent F, Djossou F, Schaerverbeke T, Criquet-Hayot A, Carrere P, Malvy D, Gaillard P, Wendling D, Société de pathologie infectieuse de langue francaise. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Medecine et maladies infectieuses. 2015 Jul:45(7):243-63. doi: 10.1016/j.medmal.2015.05.007. Epub 2015 Jun 25     [PubMed PMID: 26119684]

[40]

Martí-Carvajal A, Ramon-Pardo P, Javelle E, Simon F, Aldighieri S, Horvath H, Rodriguez-Abreu J, Reveiz L. Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review. PloS one. 2017:12(6):e0179028. doi: 10.1371/journal.pone.0179028. Epub 2017 Jun 13     [PubMed PMID: 28609439]

Level 1 (high-level) evidence

[41]

Mahendradas P, Avadhani K, Shetty R. Chikungunya and the eye: a review. Journal of ophthalmic inflammation and infection. 2013 Feb 11:3(1):35. doi: 10.1186/1869-5760-3-35. Epub 2013 Feb 11     [PubMed PMID: 23514031]

[42]

Sánchez-Duque JA, Orozco-Hernández JP, Rodríguez-Morales AJ. Rheumatic Manifestations in Patients with Chikungunya Infection: Comment on the Article by Arroyo-Ávila and Vilá. Puerto Rico health sciences journal. 2015 Dec:34(4):231-2     [PubMed PMID: 26710364]

Level 3 (low-level) evidence

[43]

Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clinical rheumatology. 2017 Jun:36(6):1335-1340. doi: 10.1007/s10067-016-3429-0. Epub 2016 Oct 4     [PubMed PMID: 27699657]

Level 1 (high-level) evidence

[44]

Parashar D, Paingankar MS, Kumar S, Gokhale MD, Sudeep AB, Shinde SB, Arankalle VA. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS neglected tropical diseases. 2013:7(9):e2405. doi: 10.1371/journal.pntd.0002405. Epub 2013 Sep 5     [PubMed PMID: 24040429]

[45]

Subudhi BB, Chattopadhyay S, Mishra P, Kumar A. Current Strategies for Inhibition of Chikungunya Infection. Viruses. 2018 May 3:10(5):. doi: 10.3390/v10050235. Epub 2018 May 3     [PubMed PMID: 29751486]

[46]

Oliveira AF, Teixeira RR, Oliveira AS, Souza AP, Silva ML, Paula SO. Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses. Molecules (Basel, Switzerland). 2017 Mar 22:22(3):. doi: 10.3390/molecules22030505. Epub 2017 Mar 22     [PubMed PMID: 28327521]

[47]

Audain G, Maher C. Prevention and Control of Worldwide Mosquito-Borne Illnesses: Nurses as Teachers. Online journal of issues in nursing. 2017 Jan 31:22(1):5. doi: 10.3912/OJIN.Vol22No01Man05. Epub 2017 Jan 31     [PubMed PMID: 28488821]

[48]

Moyes CL, Vontas J, Martins AJ, Ng LC, Koou SY, Dusfour I, Raghavendra K, Pinto J, Corbel V, David JP, Weetman D. Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. PLoS neglected tropical diseases. 2017 Jul:11(7):e0005625. doi: 10.1371/journal.pntd.0005625. Epub 2017 Jul 20     [PubMed PMID: 28727779]

[49]

Schwameis M, Buchtele N, Wadowski PP, Schoergenhofer C, Jilma B. Chikungunya vaccines in development. Human vaccines & immunotherapeutics. 2016 Mar 3:12(3):716-31. doi: 10.1080/21645515.2015.1101197. Epub     [PubMed PMID: 26554522]

[50]

Bonifay T, Lienne JF, Bagoée C, Santa F, Vesin G, Walter G, Nacher M, Vaserman N, Djossou F, Epelboin L. Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2018 Nov:37(11):2159-2164. doi: 10.1007/s10096-018-3353-0. Epub 2018 Aug 17     [PubMed PMID: 30120648]

[51]

Silva JVJ Jr, Ludwig-Begall LF, Oliveira-Filho EF, Oliveira RAS, Durães-Carvalho R, Lopes TRR, Silva DEA, Gil LHVG. A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta tropica. 2018 Dec:188():213-224. doi: 10.1016/j.actatropica.2018.09.003. Epub 2018 Sep 6     [PubMed PMID: 30195666]

Level 2 (mid-level) evidence

[52]

Huits R, De Kort J, Van Den Berg R, Chong L, Tsoumanis A, Eggermont K, Bartholomeeusen K, Ariën KK, Jacobs J, Van Esbroeck M, Bottieau E, Cnops L. Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia. PloS one. 2018:13(4):e0196630. doi: 10.1371/journal.pone.0196630. Epub 2018 Apr 30     [PubMed PMID: 29709007]

[53]

Martínez-Pulgarín DF, Chowdhury FR, Villamil-Gomez WE, Rodriguez-Morales AJ, Blohm GM, Paniz-Mondolfi AE. Ophthalmologic aspects of chikungunya infection. Travel medicine and infectious disease. 2016 Sep-Oct:14(5):451-457. doi: 10.1016/j.tmaid.2016.05.008. Epub 2016 May 26     [PubMed PMID: 27238905]

[54]

Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu RB, Shetty BK. Ocular manifestations associated with chikungunya. Ophthalmology. 2008 Feb:115(2):287-91     [PubMed PMID: 17631967]

[55]

Sharma SK, Jain S. Chikungunya: A rheumatologist's perspective. International journal of rheumatic diseases. 2018 Mar:21(3):584-601. doi: 10.1111/1756-185X.13273. Epub 2018 Feb 12     [PubMed PMID: 29431292]

Level 3 (low-level) evidence

[56]

Runowska M, Majewski D, Niklas K, Puszczewicz M. Chikungunya virus: a rheumatologist's perspective. Clinical and experimental rheumatology. 2018 May-Jun:36(3):494-501     [PubMed PMID: 29533749]

Level 3 (low-level) evidence

[57]

Naqqash MN, Gökçe A, Bakhsh A, Salim M. Insecticide resistance and its molecular basis in urban insect pests. Parasitology research. 2016 Apr:115(4):1363-73. doi: 10.1007/s00436-015-4898-9. Epub 2016 Jan 13     [PubMed PMID: 26758450]

[58]

Silva NMD, Teixeira RAG, Cardoso CG, Siqueira Junior JB, Coelho GE, Oliveira ESF. Chikungunya surveillance in Brazil: challenges in the context of Public Health. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2018 Sep 3:27(3):e2017127. doi: 10.5123/S1679-49742018000300003. Epub 2018 Sep 3     [PubMed PMID: 30183867]

[59]

Furuya-Kanamori L,Liang S,Milinovich G,Soares Magalhaes RJ,Clements AC,Hu W,Brasil P,Frentiu FD,Dunning R,Yakob L, Co-distribution and co-infection of chikungunya and dengue viruses. BMC infectious diseases. 2016 Mar 3     [PubMed PMID: 26936191]

[60]

Salam N, Mustafa S, Hafiz A, Chaudhary AA, Deeba F, Parveen S. Global prevalence and distribution of coinfection of malaria, dengue and chikungunya: a systematic review. BMC public health. 2018 Jun 8:18(1):710. doi: 10.1186/s12889-018-5626-z. Epub 2018 Jun 8     [PubMed PMID: 29879935]

Level 1 (high-level) evidence